 Austin, TX, Aug. 25, 2021 GLOBE NEWSWIRE -- QSAM Biosciences Inc. OTCQB: QSAM, a company developing next generation nuclear medicines, including Samarium-153 DOTMP CycloSam, for the treatment of cancer and related diseases and conditions, announced that the U.S. Food and Drug Administration FDA has cleared QSAMs investigational new drug IND application which allows the Company to commence Phase 1 clinical trials and the dosing of patients with bone cancer. 